EGL-001

N/A

Report date: 2025/06/23 16:14:39

Base Information

Drug NameEGL-001
Drug Alias NameEGL-001
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 inhibitorsAnti-CTLA4
TargetsInterleukin-2Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFranceSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEgle Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesEgle Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A